Skip to Main Content

Paper Details

The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma.
Leukemia
18
2021
GGPP, ISR, MM, MVA, Multiple myeloma, a, bortezomib, chromosomal translocations, fluvastatin, geranylgeranyl pyrophosphate, mevalonate, patients, plasma, plasma cell malignancy, statin, t, t(, t(4;, t(4;14), t(4;14) translocation, t(4;14)-positive cells, t(4;14)-positive multiple myeloma
Author NameAffiliation
Joseph LongoPrincess Margaret Cancer Centre, University Health Network
Joseph LongoUniversity of Toronto
Zhihua LiPrincess Margaret Cancer Centre, University Health Network
Benjamin Haibe-KainsPrincess Margaret Cancer Centre, University Health Network
Benjamin Haibe-KainsUniversity of Toronto
Benjamin Haibe-KainsOntario Institute for Cancer Research
Benjamin Haibe-KainsVector Institute
Benjamin Haibe-KainsUniversity of Toronto
Benjamin Haibe-KainsPrincess Margaret Cancer Centre, University Health Network
Benjamin Haibe-KainsUniversity of Toronto
Benjamin Haibe-KainsVector Institute
Benjamin Haibe-KainsOntario Institute for Cancer Research
Benjamin Haibe-KainsUniversity of Toronto
David W AndrewsUniversity of Toronto
David W AndrewsSunnybrook Research Institute
Jonathan J KeatsTranslational Genomics Research Institute
Trevor J PughPrincess Margaret Cancer Centre, University Health Network
Trevor J PughOntario Institute for Cancer Research
Trevor J PughUniversity of Toronto
Trevor J PughPrincess Margaret Cancer Centre, University Health Network
Trevor J PughUniversity of Toronto
Trevor J PughOntario Institute for Cancer Research
Suzanne TrudelPrincess Margaret Cancer Centre, University Health Network
Suzanne TrudelUniversity of Toronto
Suzanne TrudelPrincess Margaret Cancer Centre, University Health Network
Suzanne TrudelUniversity of Toronto
Linda Z PennPrincess Margaret Cancer Centre, University Health Network
Linda Z PennUniversity of Toronto
  • 1 - 28

Datasets

Release 1.2